Manisha P. Desai,Charles E. Dahlheim,Sunita Borsadia,Vijay H Naringrekar,Rajesh Babulal Gandhi,Manoj Nerurkar
申请号：
US16121287
公开号：
US20180360965A1
申请日:
2018.09.04
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
